retatrutide with mots c (10mg) – Vitanx Research MOTS-C & Retatrutide at the

Food and Drug Administration (FDA) for reducing cardiovascular and kidney disease risk after a major study showed significantly lower rates of heart attack and stroke among people with type 2 diabetes and established atherosclerosis

Acknowledgements The authors thank our lab members for their cooperation throughout this study

These medications work by mimicking a hormone naturally produced in your gut that helps regulate blood sugar and appetite

TRANSCEND-T2D-1: Retatrutide Phase 3 Diabetes Results (March 2026) First Phase 3 retatrutide trial in type 2 diabetes 16.8% weight loss and -2.0% A1C at 12 mg over 40 weeks